Amryt Pharma (Amryt Pharma) Price-to-Tangible-Book : (As of Jun. 02, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Price-to-Tangible-Book?

As of today (2024-06-02), Amryt Pharma's share price is $14.70. Amryt Pharma's Tangible Book per Share of Sep. 2022 for the quarter that ended in Sep. 2022 was $-2.81. Hence, Amryt Pharma's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Amryt Pharma's Price-to-Tangible-Book or its related term are showing as below:

AMYT's Price-to-Tangible-Book is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 2.325
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Amryt Pharma's share price is $14.70. Amryt Pharma's Book Value per Sharefor the quarter that ended in Sep. 2022 was $5.07. Hence, Amryt Pharma's P/B Ratio of today is 2.90.

Amryt Pharma Price-to-Tangible-Book Historical Data

The historical data trend for Amryt Pharma's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Price-to-Tangible-Book Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Price-to-Tangible-Book

Get a 7-Day Free Trial

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Price-to-Tangible-Book	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Amryt Pharma's Price-to-Tangible-Book

For the Drug Manufacturers - Specialty & Generic subindustry, Amryt Pharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amryt Pharma's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amryt Pharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Amryt Pharma's Price-to-Tangible-Book falls into.

Amryt Pharma Price-to-Tangible-Book Calculation

Amryt Pharma's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Sep. 2022 )
	=	14.70	/	-2.808
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Amryt Pharma Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).